Clinical evaluation of centrally procured generic and original esomeprazole for the treatment of acute non-variceal upper gastrointestinal bleeding
- VernacularTitle:艾司奥美拉唑集采仿制药与原研药用于急性非静脉曲张性上消化道出血的临床评价
- Author:
Si SU
1
;
Shaowei HAN
2
;
Haicai ZHUANG
1
;
Na XU
2
;
Ying LI
2
;
Xiao WANG
3
;
Kuan LI
3
Author Information
1. Dept. of Pharmacy，Shenzhen People’s Hospital （the Second Clinical Medical College，Jinan University;the First Affiliated Hospital，Southern University of Science and Technology），Guangdong Shenzhen 518020，China
2. School of Pharmacy，Guangdong Medical University，Guangdong Dongguan 523808，China
3. Dept. of Pharmacy，Shenzhen People’s Hospital （the Second Clinical Medical College，Jinan University
- Publication Type:Journal Article
- Keywords:
esomeprazole;
centrally procured generic drug;
original drug;
acute non-variceal upper gastrointestinal bleeding
- From:
China Pharmacy
2025;36(13):1635-1640
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the efficacy， safety and economics of the centrally procured generic versus original esomeprazole in the treatment of acute non-variceal upper gastrointestinal bleeding （ANVUGIB）. METHODS A retrospective collection of real-world clinical data was conducted for ANVUGIB patients who received treatment at Shenzhen People’s Hospital and University of Hong Kong-Shenzhen Hospital from January 2018 to March 2024. Patients were divided into imported original drug group （original drug group， 221 cases） and centrally procured generic drug group （generic drug group， 75 cases） according to the types of drug used. Propensity score matching （PSM） was performed at a ratio of 3∶1 to compare the clinical efficacy， safety and economics between the two groups. RESULTS Totally 241 patients were included after PSM， with 170 in the original drug group and 71 in the generic drug group. There were no significant differences between the two groups in terms of rebleeding rate， rate of second endoscopic intervention， blood transfusion rate， length of hospital stay， mortality due to gastrointestinal bleeding， 30-day readmission due to rebleeding， and overall survival rate （P＞0.05）. The incidence of adverse events among all patients in both groups also showed no statistically significant difference （P＞0.05）； furthermore， the adverse events reported by the respective hospitals to the National Center for ADR Monitoring were comparable between the two groups. After PSM， the median total drug cost and high-dose esomeprazole cost in the generic drug group were significantly lower than those in the original drug group， while the median nursing fee and bed fee were significantly higher than those in the original drug group （P＜0.05）. There was no statistically significant difference between the two groups in terms of median total hospitalization expenses， total treatment costs， laboratory fees， examination fees， material costs， or consultation fees （P＞0.05）. CONCLUSIONS The clinical efficacy and safety of centrally procured generic esomeprazole in the treatment of ANVUGIB are comparable to those of the original drug， and it is more economical.
